By Wendy Diller
Antibiotics—and especially hospital antibiotics--were made for biotech. Big Pharma often doesn't want to pursue them because their markets seem too...
Cubist ultimately wants its new hospital antibiotic Cubicin to replace the widely used vancomycin. To do that, it's got to demonstrate that Cubicin, recently approved for a single indication, is safe and effective for a broad spectrum of hard-to-treat infections. As the first company in four years to launch a new hospital antibiotic, Cubist may be a model for the handful of other small companies seeking to capitalize on the opportunity. These start-ups may be better suited than Big Pharma to address what experts see as an important but limited unmet medical need.
By Wendy Diller
Antibiotics—and especially hospital antibiotics--were made for biotech. Big Pharma often doesn't want to pursue them because their markets seem too...
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.